Although the molecular differences between embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS) have been extensively interrogated, effective therapies tailored to a particular rhabdomyosarcoma subtype have yet to emerge. Patients with ERMS have shown incremental improvement using current multimodal therapy, but survival rates for metastatic ARMS remain poor. In this issue of the JCI, Durbin and colleagues demonstrate that integrin-linked kinase (ILK) acts as a tumor suppressor in ERMS and as a proto-oncogene in ARMS, and that the opposing functions of this enzyme are dependent on the JNK1 signaling pathway (see the related article beginning on page 1558). Their findings suggest that targeting ILK may represent a focused therapeutic strategy for the treatment of ARMS.
Paul C. McDonald, Shoukat Dedhar, Charles Keller
Usage data is cumulative from May 2024 through May 2025.
Usage | JCI | PMC |
---|---|---|
Text version | 229 | 16 |
60 | 13 | |
Figure | 56 | 0 |
Citation downloads | 59 | 0 |
Totals | 404 | 29 |
Total Views | 433 |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.